{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:45:10Z","timestamp":1793684710555,"version":"4.5.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36374-9","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:14:59Z","timestamp":1771294499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative pharmacoinformatic and quantum descriptor insights from BFM\/GBTLI guidelines to phase I\/II compounds for acute lymphoblastic leukemia\u00a0(ALL)"],"prefix":"10.1038","volume":"16","author":[{"given":"Ian A. F.","family":"Bahia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad Rashad","family":"Sindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o F.","family":"Rodrigues-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edilson D.","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewulsew Kebede","family":"Tiruneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdi E. A.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto L.","family":"Fulco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas I. N.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"36374_CR1","unstructured":"Improving the childhood cancer cure rate n.d. https:\/\/www.who.int\/activities\/improving-childhood-cancer-cure-rate (accessed May 30, 2024)."},{"key":"36374_CR2","doi-asserted-by":"publisher","DOI":"10.1201\/9781351166126-2","volume-title":"Epidemiology of Pediatric Cancer","author":"C Stiller","year":"2022","unstructured":"Stiller, C. Epidemiology of Pediatric Cancer (CRC Press, 2022)."},{"key":"36374_CR3","doi-asserted-by":"publisher","unstructured":"Mohiuddin S, Zaky W, Cortes J. 45 - Overview of Pediatric Cancers. In: Hagberg C, Gottumukkala V, Riedel B, Nates J, Buggy D, editors. Perioperative Care of the Cancer Patient, New Delhi: Elsevier; 2023, p. 491\u20137. https:\/\/doi.org\/10.1016\/B978-0-323-69584-8.00045-1.","DOI":"10.1016\/B978-0-323-69584-8.00045-1"},{"key":"36374_CR4","unstructured":"Types of Cancer that Develop in Children n.d. https:\/\/www.cancer.org\/cancer\/types\/cancer-in-children\/types-of-childhood-cancers.html (accessed May 30, 2024)."},{"key":"36374_CR5","doi-asserted-by":"publisher","unstructured":"Ashok M, Tharani K, VenkataSriram S, Ramasamy K. An Investigational Study of Detecting Acute Lymphoblastic Leukemia using Computer Vision. 2023 2nd International Conference on Smart Technologies and Systems for Next Generation Computing (ICSTSN), 2023, p. 1\u20136. https:\/\/doi.org\/10.1109\/ICSTSN57873.2023.10151572.","DOI":"10.1109\/ICSTSN57873.2023.10151572"},{"key":"36374_CR6","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba, H. & Mullighan, C. G. Pediatric acute lymphoblastic leukemia. Haematologica 105, 2524\u20132539. https:\/\/doi.org\/10.3324\/haematol.2020.247031 (2020).","journal-title":"Haematologica"},{"key":"36374_CR7","doi-asserted-by":"publisher","unstructured":"Cui Y, Yang W, Shuai J, Ma Y, Xiao G, Yan Y. The global burden of childhood and adolescent leukemia and Attributable Risk Factors: An analysis of the Global Burden of Disease Study 2019 2023. https:\/\/doi.org\/10.21203\/rs.3.rs-3052004\/v1.","DOI":"10.21203\/rs.3.rs-3052004\/v1"},{"key":"36374_CR8","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"36374_CR9","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1039\/C9NJ06276A","volume":"44","author":"KS Bezerra","year":"2020","unstructured":"Bezerra, K. S. et al. Interaction energies between two antiandrogenic and one androgenic agonist receptor in the presence of a T877A mutation in prostate cancer: A quantum chemistry analysis. New J Chem 44, 5903\u20135912. https:\/\/doi.org\/10.1039\/C9NJ06276A (2020).","journal-title":"New J Chem"},{"key":"36374_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cplett.2014.07.062","volume":"612","author":"JIN Oliveira","year":"2014","unstructured":"Oliveira, J. I. N., Albuquerque, E. L., Fulco, U. L., Mauriz, P. W. & Sarmento, R. G. Electronic transport through oligopeptide chains: An artificial prototype of a molecular diode. Chem. Phys. Lett. 612, 14\u201319. https:\/\/doi.org\/10.1016\/j.cplett.2014.07.062 (2014).","journal-title":"Chem. Phys. Lett."},{"key":"36374_CR11","doi-asserted-by":"publisher","unstructured":"Yele V, Sigalapalli DK, Jupudi S, Azam MA. DFT Calculation, Molecular Docking and Molecular Dynamics Simulation Study on Substituted Phenylacetamide and Benzohydrazide Derivatives 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-779643\/v1.","DOI":"10.21203\/rs.3.rs-779643\/v1"},{"key":"36374_CR12","doi-asserted-by":"publisher","unstructured":"Web Services for the Prediction of ADMET Parameters Relevant to the Design of Neuroprotective Drugs | SpringerLink n.d. https:\/\/link.springer.com\/protocol\/https:\/\/doi.org\/10.1007\/978-1-0716-3311-3_16 (accessed December 20, 2023).","DOI":"10.1007\/978-1-0716-3311-3_16"},{"key":"36374_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrd1032","volume":"2","author":"H van de Waterbeemd","year":"2003","unstructured":"van de Waterbeemd, H. & Gifford, E. ADMET in silico modelling: Towards prediction paradise?. Nat Rev Drug Discov 2, 192\u2013204. https:\/\/doi.org\/10.1038\/nrd1032 (2003).","journal-title":"Nat Rev Drug Discov"},{"key":"36374_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3324\/haematol.2021.279059","volume":"107","author":"V Conter","year":"2022","unstructured":"Conter, V. & Ceppi, F. Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?. Haematologica 107, 356\u2013357. https:\/\/doi.org\/10.3324\/haematol.2021.279059 (2022).","journal-title":"Haematologica"},{"key":"36374_CR15","unstructured":"Protocol ALL-IC BFM 2002: Outcomes of Pediatric Acute Lymphoblastic Leukemia Treatment under Multi-Center Clinical Trial | \u041a\u043b\u0438\u043d\u0438\u0447ec\u043aa\u044f o\u043d\u043ao\u0433e\u043ca\u0442o\u043bo\u0433\u0438\u044f n.d. https:\/\/old.bloodjournal.ru\/en\/protocol-all-ic-bfm-2002-outcomes-of-pediatric-acute-lymphoblastic-leukemia-treatment-under-multi-center-clinical-trial\/, https:\/\/old.bloodjournal.ru\/en\/protocol-all-ic-bfm-2002-outcomes-of-pediatric-acute-lymphoblastic-leukemia-treatment-under-multi-center-clinical-trial\/ (accessed July 18, 2024)."},{"key":"36374_CR16","unstructured":"Dermatological toxicity of acute lymphoblastic leukemia treatment by protocol ALL IC-BFM 2002 - Valiev - Consilium Medicum n.d. https:\/\/consilium.orscience.ru\/2075-1753\/article\/view\/109889 (accessed July 18, 2024)."},{"key":"36374_CR17","unstructured":"Editor \u2013 InstaText | Write like a native speaker [Internet]. [cited 2025 May 26]. Available from: https:\/\/instatext.io\/editor\/"},{"key":"36374_CR18","volume":"10","author":"RA Agha","year":"2025","unstructured":"Agha, R. A. et al. Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline. Premier Journal of Science. 10, 100082 (2025).","journal-title":"Premier Journal of Science."},{"key":"36374_CR19","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1002\/cncr.20668","volume":"101","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian, H. et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101, 2788\u20132801. https:\/\/doi.org\/10.1002\/cncr.20668 (2004).","journal-title":"Cancer"},{"key":"36374_CR20","unstructured":"The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/33925883\/ (accessed May 30, 2024)."},{"key":"36374_CR21","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3390\/ijms24054661","volume":"24","author":"AV Ivanov","year":"2023","unstructured":"Ivanov, A. V. et al. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target. Int J Mol Sci 24, 4661. https:\/\/doi.org\/10.3390\/ijms24054661 (2023).","journal-title":"Int J Mol Sci"},{"key":"36374_CR22","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.3390\/molecules27123911","volume":"27","author":"P Obsza\u0144ski","year":"2022","unstructured":"Obsza\u0144ski, P. et al. Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia. Molecules 27, 3911. https:\/\/doi.org\/10.3390\/molecules27123911 (2022).","journal-title":"Molecules"},{"key":"36374_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","volume":"164","author":"E Brivio","year":"2022","unstructured":"Brivio, E. et al. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. Eur J Cancer 164, 1\u201317. https:\/\/doi.org\/10.1016\/j.ejca.2021.12.029 (2022).","journal-title":"Eur J Cancer"},{"key":"36374_CR24","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.gendis.2022.01.006","volume":"9","author":"Z Cao","year":"2022","unstructured":"Cao, Z. et al. Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML). Genes & Diseases 9, 1466\u20131477. https:\/\/doi.org\/10.1016\/j.gendis.2022.01.006 (2022).","journal-title":"Genes & Diseases"},{"key":"36374_CR25","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. PubChem 2023 update. Nucleic Acids Res. 51, D1373\u2013D1380. https:\/\/doi.org\/10.1093\/nar\/gkac956 (2023).","journal-title":"Nucleic Acids Res."},{"key":"36374_CR26","doi-asserted-by":"publisher","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: The DrugBank Knowledgebase for 2024. Nucleic Acids Res 2024;52:D1265\u201375. https:\/\/doi.org\/10.1093\/nar\/gkad976.","DOI":"10.1093\/nar\/gkad976"},{"key":"36374_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1021\/ed100697w","volume":"87","author":"HE Pence","year":"2010","unstructured":"Pence, H. E. & Williams, A. ChemSpider: An Online Chemical Information Resource. J Chem Educ 87, 1123\u20131124. https:\/\/doi.org\/10.1021\/ed100697w (2010).","journal-title":"J Chem Educ"},{"key":"36374_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3\u201325. https:\/\/doi.org\/10.1016\/S0169-409X(96)00423-1 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"36374_CR29","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"DF Veber","year":"2002","unstructured":"Veber, D. F. et al. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J Med Chem 45, 2615\u20132623. https:\/\/doi.org\/10.1021\/jm020017n (2002).","journal-title":"J Med Chem"},{"key":"36374_CR30","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1093\/bioinformatics\/btx491","volume":"33","author":"D Lagorce","year":"2017","unstructured":"Lagorce, D., Bouslama, L., Becot, J., Miteva, M. A. & Villoutreix, B. O. FAF-Drugs4: Free ADME-tox filtering computations for chemical biology and early stages drug discovery. Bioinformatics 33, 3658\u20133660. https:\/\/doi.org\/10.1093\/bioinformatics\/btx491 (2017).","journal-title":"Bioinformatics"},{"key":"36374_CR31","unstructured":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules | Scientific Reports n.d. https:\/\/www.nature.com\/articles\/srep42717 (accessed May 31, 2024)."},{"key":"36374_CR32","unstructured":"Molinspiration Cheminformatics n.d. https:\/\/www.molinspiration.com\/ (accessed May 30, 2024)."},{"key":"36374_CR33","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","volume":"18","author":"JD Hughes","year":"2008","unstructured":"Hughes, J. D. et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 18, 4872\u20134875. https:\/\/doi.org\/10.1016\/j.bmcl.2008.07.071 (2008).","journal-title":"Bioorg Med Chem Lett"},{"key":"36374_CR34","doi-asserted-by":"publisher","unstructured":"In\u2005Silico ADMET Traffic Lights as a Tool for the Prioritization of HTS Hits - Lobell - 2006 - ChemMedChem - Wiley Online Library n.d. https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/cmdc.200600168 (accessed May 31, 2024).","DOI":"10.1002\/cmdc.200600168"},{"key":"36374_CR35","doi-asserted-by":"crossref","unstructured":"ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties | Nucleic Acids Research | Oxford Academic n.d. https:\/\/academic.oup.com\/nar\/article\/49\/W1\/W5\/6249611?login=false (accessed May 30, 2024).","DOI":"10.1093\/nar\/gkab255"},{"key":"36374_CR36","doi-asserted-by":"publisher","unstructured":"Yang H, Lou C, Sun L, Li J, Cai Y, Wang Z, et al. admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics 2019;35:1067\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/bty707.","DOI":"10.1093\/bioinformatics\/bty707"},{"key":"36374_CR37","doi-asserted-by":"publisher","unstructured":"pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures | Journal of Medicinal Chemistry n.d. https:\/\/pubs.acs.org\/doi\/full\/https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00104 (accessed May 30, 2024).","DOI":"10.1021\/acs.jmedchem.5b00104"},{"key":"36374_CR38","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/minf.201500040","volume":"34","author":"RC Braga","year":"2015","unstructured":"Braga, R. C. et al. Pred-hERG: A Novel web-Accessible Computational Tool for Predicting Cardiac Toxicity. Mol Inform 34, 698\u2013701. https:\/\/doi.org\/10.1002\/minf.201500040 (2015).","journal-title":"Mol Inform"},{"key":"36374_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jmgm.2017.08.021","volume":"77","author":"BG de Sousa","year":"2017","unstructured":"de Sousa, B. G. et al. Molecular modelling and quantum biochemistry computations of a naturally occurring bioremediation enzyme: Alkane hydroxylase from Pseudomonas putida P1. J. Mol. Graph. Model. 77, 232\u2013239. https:\/\/doi.org\/10.1016\/j.jmgm.2017.08.021 (2017).","journal-title":"J. Mol. Graph. Model."},{"key":"36374_CR40","unstructured":"Bezerril LM, Fulco UL, Oliveira JIN, Corso G, Albuquerque EL, Freire VN, et al. Charge transport in fibrous\/not fibrous \u24233-helical and \u201e5Q , 7Q\u2026\u24233 variant peptides. Appl Phys Lett n.d."},{"key":"36374_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0009-2614(00)00488-7","volume":"323","author":"P Thanikaivelan","year":"2000","unstructured":"Thanikaivelan, P., Subramanian, V., Raghava Rao, J. & Unni, N. B. Application of quantum chemical descriptor in quantitative structure activity and structure property relationship. Chem. Phys. Lett. 323, 59\u201370. https:\/\/doi.org\/10.1016\/S0009-2614(00)00488-7 (2000).","journal-title":"Chem. Phys. Lett."},{"key":"36374_CR42","doi-asserted-by":"publisher","unstructured":"Rings in Clinical Trials and Drugs: Present and Future | Journal of Medicinal Chemistry n.d. https:\/\/pubs.acs.org\/doi\/https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00473 (accessed May 31, 2024).","DOI":"10.1021\/acs.jmedchem.2c00473"},{"key":"36374_CR43","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.drudis.2009.07.014","volume":"14","author":"TJ Ritchie","year":"2009","unstructured":"Ritchie, T. J. & Macdonald, S. J. F. The impact of aromatic ring count on compound developability \u2013 are too many aromatic rings a liability in drug design?. Drug Discovery Today 14, 1011\u20131020. https:\/\/doi.org\/10.1016\/j.drudis.2009.07.014 (2009).","journal-title":"Drug Discovery Today"},{"key":"36374_CR44","doi-asserted-by":"publisher","first-page":"9357","DOI":"10.1021\/acs.jmedchem.9b00220","volume":"62","author":"G Abrus\u00e1n","year":"2019","unstructured":"Abrus\u00e1n, G. & Marsh, J. A. Ligands and Receptors with Broad Binding Capabilities Have Common Structural Characteristics: An Antibiotic Design Perspective. J Med Chem 62, 9357\u20139374. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00220 (2019).","journal-title":"J Med Chem"},{"key":"36374_CR45","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1039\/D1MD00213A","volume":"12","author":"J Truong","year":"2021","unstructured":"Truong, J., George, A. & Holien, J. K. Analysis of physicochemical properties of protein\u2013protein interaction modulators suggests stronger alignment with the \u201crule of five\u201d. RSC Med Chem 12, 1731\u20131749. https:\/\/doi.org\/10.1039\/D1MD00213A (2021).","journal-title":"RSC Med Chem"},{"key":"36374_CR46","unstructured":"Preformulation Studies: A Versatile Tool in Formulation Design | IntechOpen n.d. https:\/\/www.intechopen.com\/chapters\/86211 (accessed May 31, 2024)."},{"key":"36374_CR47","unstructured":"Physicochemical Properties | The Handbook of Medicinal Chemistry | Books Gateway | Royal Society of Chemistry n.d. https:\/\/books.rsc.org\/books\/edited-volume\/2061\/chapter\/6376976\/Physicochemical-Properties (accessed May 31, 2024)."},{"key":"36374_CR48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.fluid.2014.01.014","volume":"368","author":"P Molyneux","year":"2014","unstructured":"Molyneux, P. Octanol\/water partition coefficients Kow: A critical examination of the value of the methylene group contribution to log Kow for homologous series of organic compounds. Fluid Phase Equilib. 368, 120\u2013141. https:\/\/doi.org\/10.1016\/j.fluid.2014.01.014 (2014).","journal-title":"Fluid Phase Equilib."},{"key":"36374_CR49","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/17460441.2017.1344210","volume":"12","author":"F Tsopelas","year":"2017","unstructured":"Tsopelas, F., Giaginis, C. & Tsantili-Kakoulidou, A. Lipophilicity and biomimetic properties to support drug discovery. Expert Opin Drug Discov 12, 885\u2013896. https:\/\/doi.org\/10.1080\/17460441.2017.1344210 (2017).","journal-title":"Expert Opin Drug Discov"},{"key":"36374_CR50","unstructured":"Modafinil: A closer look at its theoretical toxicological potential - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/37435726\/ (accessed May 31, 2024)."},{"key":"36374_CR51","doi-asserted-by":"publisher","unstructured":"Morais GC de F, Fulco UL, da Silva ED, Oliveira CBS de, Oliveira JIN. Toxicological Potential of the FDA-Approved Treatment against Monkeypox. Comment on Zovi et al. Pharmacological Agents with Antiviral Activity against Monkeypox Infection. Int. J. Mol. Sci. 2022, 23, 15941. International Journal of Translational Medicine 2023;3:183\u20136. https:\/\/doi.org\/10.3390\/ijtm3020013.","DOI":"10.3390\/ijtm3020013"},{"key":"36374_CR52","unstructured":"Quantifying the chemical beauty of drugs | Nature Chemistry n.d. https:\/\/www.nature.com\/articles\/nchem.1243 (accessed May 31, 2024)."},{"key":"36374_CR53","doi-asserted-by":"publisher","unstructured":"Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies - Jamaladdin - 2023 - Clinical Pharmacology & Therapeutics - Wiley Online Library n.d. https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/cpt.3002 (accessed May 31, 2024).","DOI":"10.1002\/cpt.3002"},{"key":"36374_CR54","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/cancers15071963","volume":"15","author":"L Bo","year":"2023","unstructured":"Bo, L. et al. The Battlefield of Chemotherapy in Pediatric Cancers. Cancers 15, 1963. https:\/\/doi.org\/10.3390\/cancers15071963 (2023).","journal-title":"Cancers"},{"key":"36374_CR55","doi-asserted-by":"publisher","unstructured":"Fagerholm U. The Role of Permeability in Drug ADME\/PK, Interactions and Toxicity, and the Permeability-Based Classification System (PCS). Burger\u2019s Medicinal Chemistry and Drug Discovery, John Wiley & Sons, Ltd; 2010, p. 367\u201380. https:\/\/doi.org\/10.1002\/0471266949.bmc163.","DOI":"10.1002\/0471266949.bmc163"},{"key":"36374_CR56","unstructured":"\u201cPrinciples and Practice of Pediatric Oncology (7th ed.)\u201d by Phillip A. Pizzo, David G. Poplack et al. n.d."},{"key":"36374_CR57","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/ph15080990","volume":"15","author":"A Kamath","year":"2022","unstructured":"Kamath, A. et al. Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response. Pharmaceuticals 15, 990. https:\/\/doi.org\/10.3390\/ph15080990 (2022).","journal-title":"Pharmaceuticals"},{"key":"36374_CR58","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1177\/10600280221148031","volume":"57","author":"A G\u00f3mez-Lumbreras","year":"2023","unstructured":"G\u00f3mez-Lumbreras, A. et al. Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS). Ann Pharmacother 57, 1137\u20131146. https:\/\/doi.org\/10.1177\/10600280221148031 (2023).","journal-title":"Ann Pharmacother"},{"key":"36374_CR59","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s12020-014-0517-2","volume":"49","author":"D Theile","year":"2015","unstructured":"Theile, D., Haefeli, W. E. & Weiss, J. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro. Endocrine 49, 842\u2013853. https:\/\/doi.org\/10.1007\/s12020-014-0517-2 (2015).","journal-title":"Endocrine"},{"key":"36374_CR60","doi-asserted-by":"publisher","unstructured":"Andrade C. Psychotropic Drugs With Long Half-Lives: Implications for Drug Discontinuation, Occasional Missed Doses, Dosing Interval, and Pregnancy Planning. J Clin Psychiatry 2022;83:22f14593. https:\/\/doi.org\/10.4088\/JCP.22f14593.","DOI":"10.4088\/JCP.22f14593"},{"key":"36374_CR61","unstructured":"The Practical Importance of Half-Life in Psychopharmacology - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/35900254\/ (accessed May 31, 2024)."},{"key":"36374_CR62","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it?. Acta Pharmaceutica Sinica B 12, 3049\u20133062. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.002 (2022).","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"36374_CR63","doi-asserted-by":"publisher","unstructured":"Boustani H, Abbasi N, Ghotaslou A, Ghalesardi OK, Zaker F, Shahidi M. Inhibition of MDM2 Using Idasanutlin (RG-7388) enhances the Chemo-sensitivity of B-ALL Cells to Daunorubicin. Iranian Journal of Pediatric Hematology & Oncology 2023. https:\/\/doi.org\/10.18502\/ijpho.v13i2.12341.","DOI":"10.18502\/ijpho.v13i2.12341"},{"key":"36374_CR64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.c.6495860.v1","author":"ME Dolan","year":"2023","unstructured":"Dolan, M. E. Data from Mapping Genes that Contribute to Daunorubicin-Induced Cytotoxicity https:\/\/doi.org\/10.1158\/0008-5472.c.6495860.v1 (2023).","journal-title":"Data from Mapping Genes that Contribute to Daunorubicin-Induced Cytotoxicity"},{"key":"36374_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-019-5377-y","volume":"19","author":"HM Al-Aamri","year":"2019","unstructured":"Al-Aamri, H. M. et al. Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia. BMC Cancer 19, 179. https:\/\/doi.org\/10.1186\/s12885-019-5377-y (2019).","journal-title":"BMC Cancer"},{"key":"36374_CR66","doi-asserted-by":"publisher","unstructured":"Adam de Beaumais T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 2011;71:575\u201384. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03867.x.","DOI":"10.1111\/j.1365-2125.2010.03867.x"},{"key":"36374_CR67","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/pgmj.71.840.639","volume":"71","author":"ST Laidlaw","year":"1995","unstructured":"Laidlaw, S. T., Reilly, J. T. & Suvarna, S. K. Fatal hepatotoxicity associated with 6-mercaptopurine therapy. Postgrad. Med. J. 71, 639. https:\/\/doi.org\/10.1136\/pgmj.71.840.639 (1995).","journal-title":"Postgrad. Med. J."},{"key":"36374_CR68","doi-asserted-by":"publisher","unstructured":"Isnani N, Perwitasari DA, Andalusia R, Mahdi HI. Evaluasi Toksisitas Hepatologi Akibat Penggunaan 6-Merkaptopurin dalam Fase Pemeliharaan pada Pasien Pediatri Kanker Leukimia Limfoblastik Akut di RS Kanker Dharmais Jakarta. Jurnal Pharmascience 2017;4. https:\/\/doi.org\/10.20527\/jps.v4i1.5757.","DOI":"10.20527\/jps.v4i1.5757"},{"key":"36374_CR69","doi-asserted-by":"crossref","unstructured":"Biology | Free Full-Text | High-Throughput Chemical Screening and Structure-Based Models to Predict hERG Inhibition n.d. https:\/\/www.mdpi.com\/2079-7737\/11\/2\/209 (accessed May 31, 2024).","DOI":"10.3390\/biology11020209"},{"key":"36374_CR70","doi-asserted-by":"publisher","unstructured":"Analysis of P-Glycoprotein Transport Cycle Reveals a New Way to Identify Efflux Inhibitors | ACS Omega n.d. https:\/\/pubs.acs.org\/doi\/https:\/\/doi.org\/10.1021\/acsomega.2c04768 (accessed May 31, 2024).","DOI":"10.1021\/acsomega.2c04768"},{"key":"36374_CR71","unstructured":"Assessment of potential drug-drug interactions among outpatients in a tertiary care hospital: Focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study) - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/36387483\/ (accessed May 31, 2024)."},{"key":"36374_CR72","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1080\/17460441.2021.1961741","volume":"16","author":"L Di","year":"2021","unstructured":"Di, L. An update on the importance of plasma protein binding in drug discovery and development. Expert Opin. Drug Discov. 16, 1453\u20131465. https:\/\/doi.org\/10.1080\/17460441.2021.1961741 (2021).","journal-title":"Expert Opin. Drug Discov."},{"key":"36374_CR73","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1021\/acs.jcim.1c00744","volume":"61","author":"TM Creanza","year":"2021","unstructured":"Creanza, T. M. et al. Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study. J Chem Inf Model 61, 4758\u20134770. https:\/\/doi.org\/10.1021\/acs.jcim.1c00744 (2021).","journal-title":"J Chem Inf Model"},{"key":"36374_CR74","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/1097-0142(19810901)48:5<1061::aid-cncr2820480502>3.0.co;2-x","volume":"48","author":"RC DeConti","year":"1981","unstructured":"DeConti, R. C. & Schoenfeld, D. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 48, 1061\u20131072. https:\/\/doi.org\/10.1002\/1097-0142(19810901)48:5%3c1061::aid-cncr2820480502%3e3.0.co;2-x (1981).","journal-title":"Cancer"},{"key":"36374_CR75","doi-asserted-by":"publisher","first-page":"18759","DOI":"10.3390\/molecules201018759","volume":"20","author":"R Censi","year":"2015","unstructured":"Censi, R. & Di Martino, P. Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs. Molecules 20, 18759\u201318776. https:\/\/doi.org\/10.3390\/molecules201018759 (2015).","journal-title":"Molecules"},{"key":"36374_CR76","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/ijms21103483","volume":"21","author":"P Ko\u017ami\u0144ski","year":"2020","unstructured":"Ko\u017ami\u0144ski, P., Halik, P. K., Chesori, R. & Gniazdowska, E. Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers. Int. J. Mol. Sci. 21, 3483. https:\/\/doi.org\/10.3390\/ijms21103483 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"36374_CR77","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2147\/IJN.S290466","volume":"16","author":"Y Zou","year":"2021","unstructured":"Zou, Y. et al. Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia. Int J Nanomedicine 16, 1127\u20131141. https:\/\/doi.org\/10.2147\/IJN.S290466 (2021).","journal-title":"Int J Nanomedicine"},{"key":"36374_CR78","doi-asserted-by":"publisher","first-page":"14172","DOI":"10.1038\/s41598-023-41426-5","volume":"13","author":"M Noga","year":"2023","unstructured":"Noga, M. et al. Development of innovative methodology for determination of 6-thioguanine in whole blood erythrocytes by HPLC\u2013PDA-based technique for medical diagnostics purposes. Sci Rep 13, 14172. https:\/\/doi.org\/10.1038\/s41598-023-41426-5 (2023).","journal-title":"Sci Rep"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36374-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36374-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36374-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:31:31Z","timestamp":1772440291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36374-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36374"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36374-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"7813"}}